Release Date:
May 26, 2011
Expiration Date:
May 26, 2012
Format:
Video/Slides
Target Audience
This educational series is intended for oncologists, hematologists, oncology nurses, oncology/specialty pharmacists, and others who are involved in the care of patients with multiple myeloma in the community setting.
Statement of Need/Program Overview
Multiple Myeloma (MM) is the second most frequent malignancy of the blood in the USA after non-Hodgkin lymphoma and causes about 1% of neoplastic diseases and 13% of hematological malignancies. Median age at diagnosis is 62 years for men and 61 years for women; only 2% of patients are younger than 40 years are diagnosed with MM. About 20,000 cases occur every year. Median survival after conventional treatments is 2-4 years, but high dose treatment followed by autologous stem-cell transplantation can extend median survival to 5-7 years. Novel drugs, for use alone and in combination with existing treatments, are increasingly being assessed for ability to further improve survival.
This educational series will educate community oncology clinicians about recently updated definitions of relapsed/refractory MM, reinforce differences in currently available therapies, and increase awareness and understanding of emerging therapies. New data will be presented to prepare them for updates to guidelines and will begin introducing additional information that will likely impact their practices in the future with a discussion of existing treatments and development of emerging therapies.
Learning Objective:
- Discuss emerging therapies for the treatment of relapsed/refractory multiple myeloma (RRMM) and identify their potential role in clinical practice.
Faculty Information and Disclosures
Sagar Lonial, MD
Director, Translational Research, B-Cell
Malignancy Program
Associate Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Dr. Lonial has disclosed that he serves as a consultant for Millennium Pharmaceuticals, Inc., Celgene, Merck, Novartis, Bristol-Myers Squibb and Onyx Pharmaceuticals.
Irene Ghobrial, MD
Director of Laboratory
Dana-Farber Cancer Institute
Assistant Professor
Department of Medicine
Harvard Medical School
Boston, Massachusetts
Dr. Ghobrial has disclosed that she serves as a consultant for Millennium Pharmaceuticals, Inc., Celgene, Novartis, Genzyme and Onyx Pharmaceuticals. She has also received grant/research support from Bristol-Myers Squibb and Millennium Pharmaceuticals, Inc.
Kenneth C. Anderson, MD
Director, Jerome Lipper Multiple Myeloma Center
Kraft Family Professor of Medicine,
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Dr. Anderson has disclosed that he serves as a consultant for Millennium Pharmaceuticals, Inc., Celgene, Merck, Novartis, Bristol-Myers Squibb and Onyx Pharmaceuticals. He is also the founder of Acetylon Pharmaceuticals.
The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CME/CPE/CNE activity.
CEC and CE Health Interactive partners and staff have no real or apparent conflicts of interest.
Instructions
To receive a statement of credit, you must:
- Review the full content of the activity and reflect upon its teachings
- Complete the questions and evaluation at the end of the activity. Your statement of credit will be issued immediately upon successful completion of the evaluation form.
Your statement of credit will be issued immediately upon successful completion of the evaluation form.
Accreditation
MEDICINE
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Creative Educational Concepts, Inc (CEC) and CE Health Interactive. CEC is accredited by the ACCME to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACY
CEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity has been assigned ACPE # 0245-0000-11-009-H01-P and will award 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.
NURSING
CEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CEC provides this activity for 0.75 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Statements of credit will be immediately online following successful completion of the posttest and evaluation.
Fee
This activity is complimentary.
Disclosure Declaration
It is the policy of CEC and CE Health Interactive to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC or CE Health Interactive for any product or manufacturer identified.
Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations.
Supporting Organization
This activity is supported by an educational grant from Onyx Pharmaceuticals
